{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:52:34Z","timestamp":1785415954084,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Previous research from our group revealed a strong association between daily defined dose (DDD)-costs and -prescriptions of antibacterial drugs in Germany (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38842562\/\" ext-link-type=\"uri\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38842562\/<\/jats:ext-link>; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39042156\/\" ext-link-type=\"uri\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39042156\/<\/jats:ext-link>). These data indicate that low costs are major driver of high prescription numbers. This study examines the relationship between bacterial resistance and DDD-prescriptions of antibacterial drugs using data from the Arzneiverordnungsreport (AVR) from 2008 to 2022 and the Antibiotic Resistance Surveillance (ARS) statistics provided by the Robert Koch Institute (RKI). We hypothesized that semi-rational or irrational prescribing behavior of antibacterial drugs is evident in Germany, i.e., prescriptions are driven to a greater extents by low DDD-costs than bacterial resistance. A bivariate correlation analysis was performed to test these models. Our data point to irrational prescribing behavior for amoxicillin, cefuroxime axetil, doxycycline, nitrofurantoin, ciprofloxacin, and clarithromycin. For amoxicillin clavulanic acid and sulfamethoxazole-trimethoprim, data point to semi-rational prescribing. For no antibacterial drug, a model pointing to rational drug prescribing was found. In conclusion, our study shows that DDD-costs exert a more significant influence on DDD-prescriptions than bacterial resistance, indicating that economic factors, rather than scientific evidence, primarily drive antibacterial drug prescriptions in outpatient settings\u00a0in Germany. It will be important to conduct similar studies on the prescription of antibacterial drugs in other countries. It will also be important to study the relation between DDD-costs and -prescriptions for other drug classes and assess the\u00a0scientific basis for these relations.<\/jats:p>","DOI":"10.1007\/s00210-024-03435-7","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:29:54Z","timestamp":1727170194000},"page":"2909-2921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Daily defined dose-costs have a stronger influence on antibacterial drug prescriptions in Germany than bacterial resistance: economic factors are more important than scientific evidence"],"prefix":"10.1007","volume":"398","author":[{"given":"Lilly Josephine","family":"Bindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"3435_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03171-y","author":"LJ Bindel","year":"2024","unstructured":"Bindel LJ, Seifert R (2024a) Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03171-y","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3435_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03288-0","author":"LJ Bindel","year":"2024","unstructured":"Bindel LJ, Seifert R (2024b) DDD-costs have a strong influence on antibacterial drug prescription in Germany: a differentiated correlation analysis from 1985 to 2022. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03288-0","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3435_CR3","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte Deutschland (BfArM) (2023) Informationen des BfArM zur eingeschr\u00e4nkten Verf\u00fcgbarkeit von Antibiotika - insbesondere f\u00fcr Kinder (actuality: 09.11.2023).&nbsp;https:\/\/www.bfarm.de\/DE\/Arzneimittel\/Arzneimittelinformationen\/Lieferengpaesse\/Archiv\/antibiotikaarchiv.html. Accessed 2 May 2024"},{"key":"3435_CR4","unstructured":"European Centre for Disease Prevention and Control (ECDC). Antimicrobial consumption Dashboard (ESAC-net). Accessed: 2024, 12.04. https:\/\/qap.ecdc.europa.eu\/public\/extensions\/AMC2_Dashboard\/AMC2_Dashboard.html#eu-consumption-tab"},{"key":"3435_CR5","doi-asserted-by":"publisher","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2021) Arzneiverordnungs-Report 2021. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-63825-5","DOI":"10.1007\/978-3-662-63825-5"},{"key":"3435_CR6","doi-asserted-by":"publisher","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2023) Arzneiverordnungs-Report 2022. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-66303-5","DOI":"10.1007\/978-3-662-66303-5"},{"key":"3435_CR7","doi-asserted-by":"publisher","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2024) Arzneiverordnungs-Report 2023. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-68371-2","DOI":"10.1007\/978-3-662-68371-2"},{"key":"3435_CR8","doi-asserted-by":"publisher","unstructured":"Machowska A, St\u00e5lsby Lundborg C. Drivers of irrational use of antibiotics in Europe. (018)Int J Environ Res Public Health. 16(1):27. https:\/\/doi.org\/10.3390\/ijerph16010027","DOI":"10.3390\/ijerph16010027"},{"key":"3435_CR9","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka MM (2012) Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24:69\u201371","journal-title":"Malawi Med J"},{"key":"3435_CR10","doi-asserted-by":"publisher","unstructured":"Retnosari Andrajati, Andri Tilaqza, Sudibyo Supardi (2017). Factors related to rational antibiotic prescriptions in community health centers in Depok City, Indonesia. Journal of Infection and Public Health, Volume 10, Issue 1, Pages 41\u201348, ISSN 1876\u20130341. https:\/\/doi.org\/10.1016\/j.jiph.2016.01.012.","DOI":"10.1016\/j.jiph.2016.01.012"},{"key":"3435_CR11","unstructured":"Robert Koch Institut (2024). ARS \u2013 Antibiotika Resistenz Surveillance. Datenbank. Resistenzstatistik. Accessed: 2024, 10.03. https:\/\/ars.rki.de\/"},{"key":"3435_CR12","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2010a) Arzneiverordnungs-Report 2008. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-540-69219-5","DOI":"10.1007\/978-3-540-69219-5"},{"key":"3435_CR13","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2010b) Arzneiverordnungs-Report 2009. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-01080-4","DOI":"10.1007\/978-3-642-01080-4"},{"key":"3435_CR14","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2011a) Arzneiverordnungs-Report 2010. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-13380-0","DOI":"10.1007\/978-3-642-13380-0"},{"key":"3435_CR15","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2011b) Arzneiverordnungs-Report 2011. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-21992-4","DOI":"10.1007\/978-3-642-21992-4"},{"key":"3435_CR16","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2012) Arzneiverordnungs-Report 2012. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-29242-2","DOI":"10.1007\/978-3-642-29242-2"},{"key":"3435_CR17","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2013) Arzneiverordnungs-Report 2013. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-37124-0","DOI":"10.1007\/978-3-642-37124-0"},{"key":"3435_CR18","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2014) Arzneiverordnungs-Report 2014. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-43487-1","DOI":"10.1007\/978-3-662-43487-1"},{"key":"3435_CR19","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2015) Arzneiverordnungs-Report 2015. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-47186-9","DOI":"10.1007\/978-3-662-47186-9"},{"key":"3435_CR20","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2016). Arzneiverordnungs-Report 2016. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-50351-5","DOI":"10.1007\/978-3-662-50351-5"},{"key":"3435_CR21","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Paffrath D (2017) Arzneiverordnungs-Report 2017. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-54630-7","DOI":"10.1007\/978-3-662-54630-7"},{"key":"3435_CR22","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2018) Arzneiverordnungs-Report 2018. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-57386-0","DOI":"10.1007\/978-3-662-57386-0"},{"key":"3435_CR23","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2019) Arzneiverordnungs-Report 2019. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-59046-1","DOI":"10.1007\/978-3-662-59046-1"},{"key":"3435_CR24","doi-asserted-by":"publisher","unstructured":"Schwabe U, and Ludwig W (2020) Arzneiverordnungs-Report 2020. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-62168-4","DOI":"10.1007\/978-3-662-62168-4"},{"key":"3435_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12992-021-00754-9","volume":"17","author":"WM Sweileh","year":"2021","unstructured":"Sweileh WM (2021) Global research publications on irrational use of antimicrobials: call for more research to contain antimicrobial resistance. Global Health 17:94. https:\/\/doi.org\/10.1186\/s12992-021-00754-9","journal-title":"Global Health"},{"key":"3435_CR26","unstructured":"World Health Organization (WHO) (2023). Antimicrobial resistance \u2013 fact sheets. (actuality: 21 November 2023). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance. Accessed: 26 July 2024"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03435-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:46:32Z","timestamp":1742294792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03435-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3435"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03435-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"25 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School () and officially registered as a doctoral thesis project for Lilly Josephine Bindel. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as a data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.S. in the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of editors acting as authors ().","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}